Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Rhythm Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Update to September Conference Participation
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals to Present at Investor Conferences in September
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.